On July 11, 2022, CytoDyn Inc. (OTCQB: CYDY), a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced a new, preclinical study in non-human primates that will evaluate the potential use in HIV of a gene therapy based on the experimental monoclonal antibody leronlimab. The research will be led by Oregon Health & Science University (OHSU) researcher Jonah Sacha, PhD, who also serves as a CytoDyn scientific advisor. The study is funded by a five-year grant of up to $5 million to OHSU from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH). The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus (AAV) vector. The study will examine if this gene-therapy approach could provide the potential for “functional cure,” i.e., sustained viral suppression in people with HIV without requiring them to take medications for the rest of their lives.
CytoDyn Announces $5 Million NIH Grant for HIV Functional Cure Study of Gene Therapy Based on Anti-CCR5 Monoclonal Antibody (Leronlimab); Grant Awarded to Oregon Health & Science University (OHSU) for Preclinical Research on One-Time Injection in Non-Human Primates
Login Or Register To Read Full Story